Houston MD Grounded by DEA Over Medicare Ban and Prescription Woes
Published Date: 9/23/2025
Notice
Summary
Dr. Rachel Kientcha-Tita from Houston lost her DEA registration because she’s barred from Medicare, Medicaid, and other federal health programs. The DEA officially revoked her license and denied her renewal after a thorough review and hearing. This means she can’t legally prescribe controlled substances through federal programs anymore, effective immediately.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked and Denied
DEA Certificate of Registration No. FK0843462 for Rachel Kientcha‑Tita, M.D., is revoked and any pending renewal or modification is denied. The Order also denies any other pending application by Dr. Kientcha‑Tita for registration in Texas. This Order is effective October 23, 2025.
Fifteen‑Year Federal Exclusion (Medicare/Medicaid)
The U.S. Department of Health and Human Services, Office of Inspector General excluded Rachel Kientcha‑Tita, M.D., from Medicare, Medicaid, and all federal health care programs effective August 20, 2017, for a period of fifteen years (through August 20, 2032). Because of that exclusion, DEA found she has been and remains excluded and revoked and denied her DEA registration.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20226, By Grace Inc. Counseling Services; Decision and Order
By Grace Inc. Counseling Services in Baltimore faced losing its DEA license because it didn’t keep good records and lied about its owner’s past drug conviction. After a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle controlled substances anymore. This affects the clinic’s ability to operate and could impact patients relying on their services.
2026-20227, St. Michael's Pharmacy; Decision and Order
St. Michael's Pharmacy in Texas had its DEA license suspended and is facing revocation because it kept filling risky drug prescriptions without fixing obvious warning signs of abuse. This affects the pharmacy’s ability to legally handle controlled substances and could impact patients relying on it. The pharmacy must now deal with these serious legal actions, which started in late 2025 and could lead to permanent closure or fines.
Previous / Next Documents
Previous: 2025-18361, Immacula Michel, M.D.; Decision and Order
Dr. Immacula Michel from Florida tried to get a DEA registration but didn’t follow the rules by prescribing controlled drugs without proper registration. Because she didn’t respond or ask for a hearing in time, her application was denied. This means she can’t legally prescribe controlled substances, and the decision is final as of September 2025.
Next: 2025-18363, Self-Regulatory Organizations; Fixed Income Clearing Corporation; Notice of Filing of Amendment No. 1, and Order Instituting Proceedings To Determine Whether To Approve or Disapprove a Proposed Rule Change, as Modified by Amendment No. 1, To Modify the GSD Rulebook Relating to Default Management and Porting With Respect to Indirect Participant Activity
The Fixed Income Clearing Corporation (FICC) wants to update its rules to better handle what happens if a company using its services can’t pay up, especially for indirect participants who use middlemen. These changes aim to make it easier to move accounts between intermediaries and improve how defaults are managed. The SEC is reviewing these updates and asking for public feedback before deciding, with potential impacts on how money and risks are handled in the system.